Agios Net Income from 2010 to 2026
| AGIO Stock | USD 28.04 0.03 0.11% |
Net Income | First Reported 2011-12-31 | Previous Quarter -112 M | Current Value -103.4 M | Quarterly Volatility 140.6 M |
Check Agios Pharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Agios Pharm's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8 M, Interest Expense of 15.4 M or Selling General Administrative of 189.3 M, as well as many indicators such as Price To Sales Ratio of 33.73, Dividend Yield of 0.0 or PTB Ratio of 1.26. Agios financial statements analysis is a perfect complement when working with Agios Pharm Valuation or Volatility modules.
Agios | Net Income | Build AI portfolio with Agios Stock |
Evaluating Agios Pharm's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Agios Pharm's fundamental strength.
Latest Agios Pharm's Net Income Growth Pattern
Below is the plot of the Net Income of Agios Pharm over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Agios Pharm financial statement analysis. It represents the amount of money remaining after all of Agios Pharm operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Agios Pharm's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Agios Pharm's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 673.73 M | 10 Years Trend |
|
Net Income |
| Timeline |
Agios Net Income Regression Statistics
| Arithmetic Mean | 82,746,452 | |
| Coefficient Of Variation | 669.26 | |
| Mean Deviation | 415,971,868 | |
| Median | (53,504,000) | |
| Standard Deviation | 553,785,395 | |
| Sample Variance | 306678.3T | |
| Range | 2B | |
| R-Value | 0.42 | |
| Mean Square Error | 268221.2T | |
| R-Squared | 0.18 | |
| Significance | 0.09 | |
| Slope | 46,535,220 | |
| Total Sum of Squares | 4906852.2T |
Agios Net Income History
Other Fundumenentals of Agios Pharm
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Agios Pharm Net Income component correlations
About Agios Pharm Financial Statements
Agios Pharm investors utilize fundamental indicators, such as Net Income, to predict how Agios Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Income | 606.4 M | 636.7 M | |
| Net Income From Continuing Ops | 774.8 M | 813.5 M | |
| Net Loss | -266.6 M | -253.2 M | |
| Net Loss | (7.12) | (6.76) | |
| Net Income Per E B T | 1.00 | 1.05 |
Pair Trading with Agios Pharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.Moving against Agios Stock
| 0.64 | DSGN | Design Therapeutics | PairCorr |
| 0.45 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.42 | KYTX | Kyverna Therapeutics | PairCorr |
The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.
The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Agios Pharm Correlation against competitors. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Will Biotechnology sector continue expanding? Could Agios diversify its offerings? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Agios Pharm data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (7.01) | Revenue Per Share | Quarterly Revenue Growth 0.437 | Return On Assets | Return On Equity |
Agios Pharm's market price often diverges from its book value, the accounting figure shown on Agios's balance sheet. Smart investors calculate Agios Pharm's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Agios Pharm's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Agios Pharm's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Agios Pharm represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.